Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reuters about GOVX : http://www.reuters.com/article/health-zika-factbox-idUSKCN0VC2FP
$GOVX HIDDEN GEM FOLKS
seeking alpha dropped an article today, doesnt even mention GOVX!!! They don't even know yet, or they dont want you to know just yet
GOVX ~ Concerns Zika could hit Brazil’s tourism
http://thebricspost.com/concerns-zika-could-hit-brazils-tourism/#.VrLhWMv2bv8
GOVX Zika virus vaccine play~ Zika virus: Returning Britons face 28-day ban on blood donations as WHO warns Europe is at risk
NHS announces ban on blood donations from travellers returning from affected regions.
5 hours ago
By Mark Piggott
Zika outbreak: World Health Organization declares global emergency
Zika virus: Facts, symptoms, microcephaly – everything you need to know
http://www.ibtimes.co.uk/
GOVX is the big $$$ Zika virus play. Looking to make big $$$ ahead on this one.
Zika Virus Leads Florida to Declare Health Emergency in 4 Counties
At least 9 cases of mosquito-borne illness have been detected in state
http://www.wsj.com/articles/zika-virus-leads-florida-to-declare-health-emergency-in-4-counties-1454532208?mod=e2tw
Riddle me this batman, what happens to the poor lady who doesn't receive the vaccine, that I might point out, does not protect against all HPV strains, contracts HPV. There is no cure. Oh too bad so sad can't do anything for you.
c'mon, thats like saying the "polio vaccine" is useless.
Do you know how many young ladies get the HPV vaccine every year?????
Let's pray that a cure will be found.-reconranger
I don't not know what your background education is but if you have had any education in genetics or molecular biology, a cure is so much better than a vaccine. A vaccine such as a flu shot is a shot in the dark based on the strain of flu from the previous year. While it may prevent you from contracting the flu from the previous year, the strain may and probably will mutate so that the vaccine is rendered useless. For instance H1N1 was a mutation of some of the flu's proteins. The flu has been around for quite some time and will not go away.
Now a cure... Well geez whiz kidos we can eradicate Zika bottom line, i.e. Small pox and polio
$GOVX HUGE DD FROM UNIVERSITY OF GEORGIA
Ted Ross, (above) director of UGA's Center for Vaccines and Immunology: "We believe that the expertise of our researchers combined with GeoVax's vaccine platform can accelerate the development and testing of a vaccine for this fast-spreading viral disease," Ross said
"This important partnership with GeoVax is consistent with one of our highest priorities, namely to work effectively with industry to address important challenges facing the state, the nation and the world," said David Lee, UGA vice president for research. -
I hope you read the GOVX news and then the University of Georgia news of the collaboration ( I posted that link also). This is going to be huge. I bet wall street runs GOVX over .50 ahead. I am patient. This will get hotter in the days and weeks ahead.
They are the only ones making a vaccine! The university of Georgia does not collaborate to make vaccines with scams. The GOVX news is real. Read the link. GOVX could run over .50 ahead.
GOVX is a loser. Tank City! Been in FDA phase I & II for over 15 years. Go ahead and throw away your money. UofG more grant money. Good luck playing the momo.
The university of Georgia does not collaborate to make vaccines with scams. The GOVX news is real. Read the link. GOVX could run over .50 ahead.
GOVX HUGE news on a collaborative research agreement with GeoVax Labs Inc. and University of Georgia to develop and test a vaccine to prevent the emerging and virulent Zika virus infection.
http://news.uga.edu/releases/article/university-of-georgia-geovax-zika-vaccine-0216/
University of Georgia to collaborate with GeoVax on Zika vaccine
February 3, 2016
Athens, Ga. - The University of Georgia announced today that it has entered into a collaborative research agreement with GeoVax Labs Inc. to develop and test a vaccine to prevent the emerging and virulent Zika virus infection.
The collaboration will combine the vaccine development expertise of UGA researchers led by Ted Ross, director of UGA's Center for Vaccines and Immunology, with GeoVax's novel vaccine platform technology. Ross, a professor and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine, joined UGA last fall.
The World Health Organization on Monday declared Zika virus an international health emergency, noting that Zika is spreading explosively and could affect as many as 4 million people in the Americas by the end of the year. The mosquito-transmitted virus is linked with birth defects in thousands of babies in Brazil, and more recently, with Guillain-Barré syndrome, a disorder in which the body's immune system attacks the nervous system. The virus is anticipated to spread to countries throughout the Western Hemisphere, with the exception of Canada and Chile.
There is no proven vaccine or treatment for Zika, which is closely related to yellow fever, dengue and chikungunya viruses, also transmitted to people by mosquitoes.
"This important partnership with GeoVax is consistent with one of our highest priorities, namely to work effectively with industry to address important challenges facing the state, the nation and the world," said David Lee, UGA vice president for research.
"We believe that the expertise of our researchers combined with GeoVax's vaccine platform can accelerate the development and testing of a vaccine for this fast-spreading viral disease," Ross said.
His research group focuses on designing, developing and testing vaccines-including what are called VLP-based vaccines—for emerging viral diseases including dengue, chikungunya and Ebola, as well as influenza, respiratory syncytial virus and HIV/AIDS.
VLPs—virus-like particles—mimic a live virus but do not contain genetic material; they cannot replicate or cause infection, yet they elicit a strong immune response in the cells of the person being vaccinated.
Ross explained that vaccines made with VLPs give the immune system a head start in fighting infection.
"When a person vaccinated with a VLP virus is infected by the real virus, the immune system is ready to fight back," he said.
Vaccines using VLPs on the market today are used to prevent hepatitis and Papilloma virus infections, and others are in development.
GeoVax's novel vaccine platform technology takes a different approach with VLPs. Instead of introducing VLPs in the vaccine, it uses recombinant DNA or recombinant viruses to produce VLPs in the person being vaccinated so that they more closely resemble the virus generated in a person's body during a natural infection. The company's MVA-VLP platform is focused on vaccines against HIV and hemorrhagic fever viruses, including Ebola, Marburg and Lassa. The HIV vaccine has been proven safe in human clinical trials involving over 500 individuals. It also is being evaluated for use in cancer vaccines.
"We believe our MVA-VLP vaccine platform is uniquely suited to apply to the Zika virus," said Robert McNally, GeoVax president and CEO.
Ross' lab will test Zika VLP vaccines developed in his lab and VLP vaccines developed with GeoVax's vaccine platform in pre-clinical animal models.
In addition to Ross, UGA researchers working on the Zika vaccine include Ralph Tripp, ? Georgia Research Alliance Chair in Vaccine and Therapeutic Development; Biao He, Georgia Research Alliance Distinguished Investigator and Fred C. Davison Distinguished University Chair in Veterinary Medicine; and Mark Tompkins, associate professor of infectious diseases.
University of Georgia
The University of Georgia is committed to improving human health, safeguarding our world and improving lives through the land-grant activities. Its rapidly expanding research enterprise addresses infectious disease threats worldwide by developing successful countermeasures, including vaccines, therapeutics and diagnostics, through partnerships with industry. For more information, visit www.uga.edu.
GeoVax
GeoVax Labs Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Virus Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The company also recently began a program to evaluate the use of its MVA-VLP platform in cancer immunotherapy. GeoVax's most advanced development programs are focused on vaccines against HIV and hemorrhagic fever viruses (Ebola, Marburg and Lassa). GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear. For more information, visit www.geovax.com/.
Filed under: Medical Science, Health Sciences, Infectious Diseases, Vet Med, Science, Technology .
GOVX is a pump and dump > avoid or play quick momo.
Read that little tidbit earlier today - as I hold a small (and quite red at present) batch of HEB shares & pay attention to what they PR.
Ampligen 'could' be effective against Zika - it certainly appeared to be against Ebola in some tests done at USAMRIID late 2014 - very early 2015.
HEB would have the added advantage that they don't need to do any new development on Ampligen. They just have to find a partner with the ability to do some preclinical testing of it on Zika models.
Interesting,.... thanks for the post Digger.
$HEB Zika-News
....and expanding research on the use of our experimental drug Ampligen and Alferon N as an early onset broad spectrum antivirals for diseases such as MERS, Ebola virus, Equine Encephalitis and, given the new pandemic threat, the Zika virus. Previous studies (preclinical) have shown that both Ampligen and interferon are active against the flavivirus family of viruses which includes the West Nile virus and Zika virus.
http://finance.yahoo.com/news/hemispherx-biopharma-introduces-voluntary-stock-133000887.html
Good board here!
Ok if you say so-reconranger
$BIEI is a ZIKA PLAY. Reread the PR. Dont hate
BIEI is not the answer! Stop pumping-reconranger
People are not the problem!
The bloody mosquitoes are.
And Zika knows it.
Peru implements measures against zika virus in airports, ports and borders
To prevent the spread, vice minister of Public Health, Percy Minaya informed that vigilance at all ports, borders and airports in Peru will be increased. He said that if an individual shows signs of symptoms similar to zika, they will be permitted to take a blood sample.
http://www.peruthisweek.com/news-peru-implements-measures-against-zika-in-airports-ports-and-borders-108686
BIEI is fixing to sign a JV with a brazilian pharma in order to use their patented technology to cure this pandemic of Zika virus
6. What are the long-term risks if you contract Zika?
By far one of the more popular themes among all the questions for Morse was about the long-term risks of contracting Zika virus.
He said: “We think once you’re recovered that the virus is probably gone from the body.” (Versus something like chickenpox, which stays in the body.)
One reader asked if a woman who contracted Zika, then become pregnant much later would still be at risk to see birth defects in her fetus.
It’s too soon to know for sure, Morse said, but probably her fetus will be OK: “There is insufficient data on the question of whether it is safe for a woman who has been infected with Zika to get pregnant later. But given what we know so far, she should probably be safe after recovery.”
Another commenter chimed in that, according to the CDC, “there is no threat to later pregnancies. The threat is when the pregnant mother becomes infected, and the threat is only for the baby currently being carried.”
marketwatch.com
http://www.marketwatch.com/story/your-questions-about-zika-virus-answered-by-an-expert-2016-02-01
Sexually transmitted case of Zika virus reported in Dallas County
http://www.fox10phoenix.com/news/83986692-story
$GNBT HUGE DD CONTINUED:
Merger/Acquisition
September 30, 2015 (you can scroll down and see this posted)
http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=7985278
Mr. Lawrence Salvo
Chief Executive Officer and President
Hema Diagnostic Systems LLC
Lawrence Salvo, President and CEO of Hema Diagnostic Systems said today: "There are synergies between the HDS product development work and the research and development work undertaken by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, in the area of vaccines for infectious diseases. HDS will seek to leverage the Generex experience and expertise in infectious diseases to incorporate avian and swine influenzas into the HDS product line, thereby expanding exposure and appeal to the world markets. Certainly, we welcome this opportunity which should provide significate positive results for each company."
Mr. Salvo further stated: "Therefore, in cooperation with Generex, HDS will immediately undertake the required steps to gain FDA approvals and to expand those approvals to include additional HDS products."
Mr. Salvo also stated: "Of significant interest in this process will be the introduction of our Express II system which will be the first price competitive alternative to the established, cumbersome and difficult to use cassette system which has existed in the world markets for the past 30 years."
http://antigenexpress.com/index.html
The technologies developed at Antigen Express are novel and highly complementary to existing approaches of immune modification. Therefore, the company is uniquely positioned to develop partnerships where Antigen Express technology enhances or augments the corporate partners’ technology or product portfolios.
Antigen Express, Inc. - A division of Generex Biotechnology Corp
$GNBT HUGE DD: HEMA DIAGNOSTIC SYSTEMS Announces the Execution of A Non-Binding Letter Of Intent with Generex Biotechnology Corporation.
MIRAMAR, FL / October 1, 2015 / Hema Diagnostic Systems, LLC (HDS), a leading U.S. manufacturer of in-vitro, point-of-care medical devices for infectious diseases, announced today the execution of a non-binding letter of intent (LOI) with Generex Biotechnology Corporation (Generex) (www.generex.com) (GNBT) whereby Generex will acquire a 51% equity interest in HDS in exchange for a purchase price of $15,000,000.
As HDS has been in the world markets for many years, it has developed relationships in many countries throughout Africa, South and Central America, Eastern Europe and into the Arab Gulf. These relationships, many of which are direct with health ministries, open certain doors for us.
HDS is also an approved vendor under UNESCO, UNICEF, UNPD and Aramco.
The current HDS product line includes rapid tests for HIV, Malaria, Syphilis, Hepatitis-B, Hepatitis-C and Tuberculosis. Products under development include Dengue IgG/IgM, Dengue NS1, Ebola and Anthrax (LF/PA).
http://finance.yahoo.com/news/hema-diagnostic-systems-discussions-equity-164300843.html
A possible cure for the Zika virus could send BIEI surging with today's news!
Agreed. Biei potential huge!
$BIEI NEWS OUT 40MILL FLOAT
Premier is working, with Auramedi's support, on investigations to apply Premier’s extracorporeal technology toward finding a cure for the Zika and Dengue viruses.
https://finance.yahoo.com/news/premier-biomedical-announces-intended-6-143000696.html
SpringStar Joins Fight Against Zika and Dengue Fever
SpringStar, Inc stepped up their efforts to fight against mosquitoes that transmit Zika. The company’s Mosquito Trap-N-Kill™, the only EPA-registered trap of its type, targets mosquitoes that spread Zika and dengue fever.
http://investingnews.com/daily/life-science-investing/biotech-investing/springstar-joins-fight-against-zika-and-dengue-fever/
Vical is working on a dengue treatment. However the company is faced hardship with other pipeline ventures.
Don't know if they will jump into zika territory
From vicals website:
"Tetravalent dengue vaccine (TVDV) is a plasmid DNA-based infectious disease vaccine in clinical development in humans for the prevention of all 4 dengue virus serotypes. Vical manufactured TVDV under contract with the Naval Medical Research Center, who has conducted Phase 1 testing of this vaccine. TVDV utilizes Vical’s proprietary adjuvant formulation, Vaxfectin®, to increase immune responses."
XON 01/28/16 ARTICLE MENTIONS OXITEC GENETIC MODIFIED MOSQUITOS.
http://theantimedia.org/zika-outbreak-epicenter-in-same-area-where-gm-mosquitoes-were-released-in-2015/
STAY UP-TO-DATE WITH ZIKA ON IHUB. FOLLOW THE ZIKA BOARD:
http://investorshub.advfn.com/***Zika-virus-%28Shorts-and-Longs%29-%28ZIKA%29***-30666/
01/29/2016 Third ZIKA case confirmed in New York
http://www.msn.com/en-us/news/us/third-zika-case-confirmed-in-new-york/ar-BBoQrQI
01/16/2016 First-US-case-of-Zika-detected-in-Arkansas
http://www.sott.net/article/311016-First-US-case-of-Zika-virus-detected-in-Arkansas
I own both INO and NNVC!
INO has moved up some in recent years while NNVC has dived due to the great time needed, apparently, to vet their viricides for the FDA.
I expect both to move to 3 figures in due time - INO 1st!!
Zika virus plays INO, GNVC, XON, VPRO, GNBT, NNVC
I figured someone had already started this group. Great idea. So what do we have so far? How many potential companies are working on a vaccine?
I thought Zika and Dengue were pretty close! Almost where DengueCide would/might work with no tweaking required.
I get the impression that DengueCide might work on Zika!
Of course we don't really know if it works on Dengue, yet.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
106
|
Created
|
01/29/16
|
Type
|
Free
|
Moderator GhostInTheMatrix | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |